ストックスクリーナーアプリを入手
1.68
6.67%
-0.12
前日終値:
$1.80
開ける：
$1.79
24時間の取引高:
908.23K
Relative Volume:
0.88
時価総額：
$140.13M
収益：
$13.86M
当期純損益:
$-81.74M
株価収益率:
-1.2887
EPS:
-1.3036
ネットキャッシュフロー:
$-66.98M
1週間 パフォーマンス:
-17.24%
1か月 パフォーマンス:
-49.70%
6か月 パフォーマンス:
-1.18%
1年 パフォーマンス:
-49.85%
1日の値動き範囲:
$1.66
$1.79
1週間の範囲:
$1.66
$2.08
52週間の値動き範囲:
$1.03
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Compare PYXS vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.68 | 140.13M | 13.86M | -81.74M | -66.98M | -1.3036 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-08-03 | 開始されました | Wells Fargo | Overweight |
| 2026-05-05 | 開始されました | Wedbush | Outperform |
| 2025-11-03 | 再開されました | Stifel | Buy |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2024-11-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-08-08 | 開始されました | Stifel | Buy |
| 2024-05-07 | 再開されました | Jefferies | Buy |
| 2024-02-09 | 開始されました | BTIG Research | Buy |
| 2024-01-23 | 開始されました | Leerink Partners | Outperform |
| 2023-09-05 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-11-02 | 開始されました | BofA Securities | Neutral |
| 2021-11-02 | 開始されました | Credit Suisse | Outperform |
| 2021-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Pyxis Oncology Inc (PYXS) 最新ニュース
Form 4 Pyxis Oncology Inc For: 10 October By Investing.com - Investing.com South Africa
Form 4 Pyxis Oncology Inc For: 10 October By Investing.com - Investing.com Nigeria
Form 4 Pyxis Oncology Inc For: 10 October By Investing.com - Investing.com UK
Warrants for 4.9 million shares are included in a passive stake in Pyxis Oncology (PYXS). - Stock Titan
Warrants bought at Pyxis Oncology (PYXS) cannot be exercised yet, and their count is corrected. - Stock Titan
Pyxis Oncology stock fell 9.82 percent on October 6 after financing - AD HOC NEWS
A passive holder reports over 5% of Pyxis Oncology (PYXS), with some warrants excluded. - stocktitan.net
Form 4 Pyxis Oncology Inc For: 2 October By Investing.com - Investing.com Nigeria
Form 4 Pyxis Oncology Inc For: 2 October By Investing.com - Investing.com Canada
GordonMD Discloses 17.5% Stake in Pyxis Oncology Including Warrants - Kalkine Media
A 10% owner buys $2.90 share-and-warrant packages in Pyxis Oncology (PYXS). - Stock Titan
An ownership cap restricts warrant exercise for a Pyxis Oncology (PYXS) investor. - Stock Titan
Pyxis Oncology Closes $110 Million Public Offering to Advance MICVO Clinical Development - Quiver Quantitative
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering - GlobeNewswire
Pyxis Oncology Raises $102.8 Million Net in Underwritten Equity Offering Led by Leerink, Guggenheim, Wells Fargo - TradingView
Form 424B5 Pyxis Oncology Inc For: 1 October By Investing.com - Investing.com Canada
Latham Advises on Pyxis Oncology’s Up to US$282.6 Million Public Offering - Legal Desire
Pyxis Oncology Prices Public Offering of Common Stock, Warrants - marketscreener.com
Pyxis Oncology prices $110 million public offering - Investing.com
Pyxis Oncology prices $110 million public offering By Investing.com - Investing.com Canada
Pyxis Oncology launches public offering to fund MICVO Phase 3 development - scanx.trade
Pyxis Oncology stock falls on public offering announcement - Yahoo Finance UK
Pyxis Oncology stock falls on public offering announcement - Yahoo Finance
Pyxis Oncology launches public offering of stock and warrants By Investing.com - Investing.com Canada
Pyxis Oncology Announces Proposed Registered Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants - Quiver Quantitative
Pyxis Oncology (Nasdaq:PYXS)Stock Analysis - Simply Wall Street
Pyxis Oncology Inc (NASDAQ: PYXS) Share Price, PYXS Stock News, PYXS Share Price & Updates - Kalkine
Pyxis Oncology: Setbacks Costing Nearly 2 Years Of Recovery (NASDAQ:PYXS) - Seeking Alpha
Wells Fargo raises Pyxis Oncology stock price target on MICVO data By Investing.com - Investing.com South Africa
Wedbush raises Pyxis Oncology stock price target on trial data By Investing.com - Investing.com South Africa
Wedbush raises Pyxis Oncology stock price target on trial data By Investing.com - Investing.com Nigeria
Wells Fargo raises Pyxis Oncology stock price target on MICVO data By Investing.com - Investing.com Australia
Enterprise value to revenue forward of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Pyxis Oncology stock price target raised to $8 by H.C. Wainwright By Investing.com - Investing.com Australia
Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know - webull.com
Pyxis Oncology (NASDAQ: PYXS) to Launch Phase 3 Trial for MICVO in Mid-2027 Following Promising Phase 1 Results - Kalkine Media
Pyxis Oncology stock price target raised to $8 by H.C. Wainwright - Investing.com Nigeria
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $6 to $19 - Moomoo
Pyxis Oncology stock price target raised to $8 by H.C. Wainwright - Investing.com Australia
Wells Fargo raises Pyxis Oncology stock price target on MICVO data - Investing.com Australia
Pyxis Oncology stock price target raised to $8 by H.C. Wainwright - investing.com
Wells Fargo raises Pyxis Oncology stock price target on MICVO data - Investing.com Nigeria
Pyxis Oncology stock price target raised to $8 by H.C. Wainwright - Investing.com Canada
Wedbush raises Pyxis Oncology stock price target on trial data By Investing.com - Investing.com Australia
Wells Fargo raises Pyxis Oncology stock price target on MICVO data - Investing.com Canada
Wells Fargo raises Pyxis Oncology stock price target on MICVO data - Investing.com UK
Wells Fargo raises Pyxis Oncology stock price target on MICVO data - Investing.com
Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell CarcinomaSlideshow (NASDAQ:PYXS) 2026-09-10 - Seeking Alpha
Wedbush raises Pyxis Oncology stock price target on trial data - investing.com
Wedbush raises Pyxis Oncology stock price target on trial data - Investing.com
Pyxis Oncology Inc (PYXS) 財務データ
収益
当期純利益
現金流量
EPS
4.22%
大文字化:
|
ボリューム (24 時間):